Hepatology

News

06 Sep 2021
A synthetic CDK4/6 inhibitor exerts antitumor effects by forcing RB1 tumor-suppressor into an active status, but its single administration is not sufficiently effective. We find its combinatorial administration with an IKKβ inhibitor is significantly more effective in hepatocellular carcinoma treatment. Also, blockage of the IKK-NF-κB or AKT pathway enhances its effects on RB1-intact K-Ras mutated lung and colon cancers. CDK4/6 inhibitors have potential to treat various RB1-intact cancers when combined with an appropriate kinase inhibitor.
His-CYGB deactivates HSCs and inhibits liver fibrosis
15 Feb 2021
Osaka City University paves way for liver health by discovering the use of cytoglobin in anti-fibrotic therapy.
19 Jan 2021
New ‘armoured’ T cells attack cancer without being suppressed by drugs given to transplant patients to avoid organ rejection.

Events

Sorry, no events coming up for this topic.

Researchers

Sorry, no researchers coming up for this topic.